COMMUNIQUÉS West-GlobeNewswire

Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
08/08/2019
EMERYVILLE, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, [...]
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/08/2019
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and orphan genetic [...]
Progenics Pharmaceuticals Announces Additional Governance Enhancements
08/08/2019
Board Accepts Resignations of Directors Peter J. Crowley and Michael D. Kishbauch, Effective October 17, 2019 Board Names New Committee Chairs Board Adopts Stock Ownership Guidelines for Directors and Officers Members [...]
Ziopharm Oncology Reports Second Quarter 2019 Financial Results
08/08/2019
– FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors at the National Cancer Institute (NCI) – – Exclusive license from NCI for library of T-cell receptors (TCRs) [...]
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
08/08/2019
Conference call to be held on August 8, 2019 at 8:30 am EDT/1:30 pm BST LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next- [...]
Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma
08/08/2019
BOSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted [...]
Albireo Reports Second Quarter 2019 Financial Results
08/08/2019
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON, Aug. 08, 2019 (GLOBE [...]
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
08/08/2019
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/08/2019
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near [...]
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
08/08/2019
Top-line Phase 2 refractory status epilepticus (RSE) data on-track for Q3 2019 Scott Braunstein, MD appointed as CEO Nicole Vitullo appointed as Chairman of the Board RADNOR, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- [...]
Agraflora Organics International Inc.
08/08/2019
COMMUNIQUÉ DE PRESSE AgraFlora Organics annonce la signature d’une lettre d'intention non contraignante pour la commercialisation et la distribution de CBD et entame des discussions avec l’un des plus importants [...]
REPEAT - AgraFlora Organics Enters Into Non-Binding CBD Commercialization and Distribution LOI; Commences Discussions With One of Canada’s Largest Food Retailers To Achieve National Branded and Private Label CBD Product Exposure
08/08/2019
VANCOUVER, British Columbia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]
Recro Pharma Reports Second Quarter 2019 Financial Results
08/08/2019
Record Results and Raising Guidance Announces Plan to Spin Acute Care Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a [...]
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
08/08/2019
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin [...]
Orchard Therapeutics Reports Second Quarter 2019 Financial Results and Builds Momentum Ahead of Regulatory Filings
08/08/2019
Metachromatic Leukodystrophy (MLD) MAA Submission and Initiation of ADA-SCID Rolling BLA Expected in the First Half of 2020; OTL-103 Recently Granted RMAT Designation for Wiskott-Aldrich Syndrome (WAS) MLD and [...]
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
08/08/2019
DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today [...]
Cronos Group Inc. Announces Second Quarter and First-Half 2019 Results
08/08/2019
Opened Cronos Device Labs, New Global R&D Center in Israel Appointed Dr. Todd Abraham as Chief Innovation Officer Announced Agreement to Acquire State-of-the-Art Fermentation Facility Established New Growth [...]
Neos Therapeutics Reports Second Quarter 2019 Financial Results
08/08/2019
– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its [...]
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
08/08/2019
Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on track for readout of topline results in 2H [...]

Pages